Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 16;22(5):1150–1160. doi: 10.1158/1078-0432.CCR-15-1522

Figure 4. Antitumor effects of SAR405838 in DDLPS xenograft models.

Figure 4

A) mRNA expression levels from DDLPS xenografts following SAR405838 treatment. B) Protein expression levels of selected genes in response to time (6–72 h) and a single dose (100 and 200 mg/kg, p.o.) of SAR405838 or vehicle. Data represents mean ± SEM, n=3. Oral administration of SAR405838 (50, 100 or 200 mg/kg) or vehicle control in nude mice (n=7–8 per group) bearing s.c. Lipo863 (C) and Lipo246 (D) xenograft tumors, which significantly decreased tumor volumes (± SEM) and (E) tumor weights (mean tumor weight at termination for each group of mice was recorded ± SEM; t-test: *=P<0.05, **=P<0.01, ***=P<0.001). (F) 200 mg/kg/wk was orally administered to Lipo246 xenograft bearing mice (n=5); robust in vivo antitumor activity was seen, and after two treatments tumors were completely eradicated in mice.